Literature DB >> 4007034

Steady-state concentration of cotinine as a measure of nicotine-intake by smokers.

R L Galeazzi, P Daenens, M Gugger.   

Abstract

Measurement of plasma cotinine, the major metabolite of nicotine, is usually done to determine nicotine-intake in smokers. Cotinine is used instead of nicotine because it has a much longer half-life than the mother substance and its plasma concentrations are therefore less dependent on the exact times of blood sampling. However, the linearity of the relationship between nicotine-intake and cotinine level in plasma has never been proven. Therefore cotinine was measured in 6 healthy volunteers infused over 4 days with several doses of nicotine i.v. up to 480 micrograms/kg/day. Cotinine concentrations in plasma were shown to be linearly and directly related to nicotine intake. The concentration of cotinine showed little variation during and for up to 2 h after the last dose of nicotine. Therefore, cotinine can be used as an epidemiological marker of nicotine intake if it is measured around the time of the last cigarette of the day.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4007034     DOI: 10.1007/bf00543327

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Cotinine excretion and daily cigarette smoking in habituated smokers.

Authors:  S Matsukura; N Sakamoto; Y Seino; T Tamada; H Matsuyama; H Muranaka
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

2.  The effect of smoking on nicotine metabolism in vivo in man.

Authors:  A H Beckett; J W Gorrod; P Jenner
Journal:  J Pharm Pharmacol       Date:  1971-12       Impact factor: 3.765

3.  A possible relation between pKa 1 and lipid solubility and the amounts excreted in urine of some tobacco alkaloids given to man.

Authors:  A H Beckett; J W Gorrod; P Jenner
Journal:  J Pharm Pharmacol       Date:  1972-02       Impact factor: 3.765

4.  Smoker intake from cigarettes in the 1-mg Federal Trade Commission tar class.

Authors:  G B Gori; C J Lynch
Journal:  Regul Toxicol Pharmacol       Date:  1983-06       Impact factor: 3.271

5.  Daily intake of nicotine during cigarette smoking.

Authors:  N L Benowitz; P Jacob
Journal:  Clin Pharmacol Ther       Date:  1984-04       Impact factor: 6.875

6.  Plasma nicotine and cotinine concentrations in habitual smokeless tobacco users.

Authors:  E R Gritz; V Baer-Weiss; N L Benowitz; H Van Vunakis; M E Jarvik
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

7.  Disposition kinetics and effects of intravenous nicotine.

Authors:  J Rosenberg; N L Benowitz; P Jacob; K M Wilson
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

8.  Cotinine disposition and effects.

Authors:  N L Benowitz; F Kuyt; P Jacob; R T Jones; A L Osman
Journal:  Clin Pharmacol Ther       Date:  1983-11       Impact factor: 6.875

9.  Smokers of low-yield cigarettes do not consume less nicotine.

Authors:  N L Benowitz; S M Hall; R I Herning; P Jacob; R T Jones; A L Osman
Journal:  N Engl J Med       Date:  1983-07-21       Impact factor: 91.245

  9 in total
  14 in total

1.  Open randomised trial of intermittent very low energy diet together with nicotine gum for stopping smoking in women who gained weight in previous attempts to quit.

Authors:  T Danielsson; S Rössner; A Westin
Journal:  BMJ       Date:  1999-08-21

2.  Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes.

Authors:  P Jacob; L Yu; A T Shulgin; N L Benowitz
Journal:  Am J Public Health       Date:  1999-05       Impact factor: 9.308

Review 3.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

4.  The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers.

Authors:  M Curvall; C E Elwin; E Kazemi-Vala; C Warholm; C R Enzell
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  In vivo versus in vitro airway surface liquid nicotine levels following cigarette smoke exposure.

Authors:  Lucy A Clunes; Arlene Bridges; Neil Alexis; Robert Tarran
Journal:  J Anal Toxicol       Date:  2008-04       Impact factor: 3.367

Review 6.  Nicotine treatment in ulcerative colitis. Current status.

Authors:  J Rhodes; G Thomas
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

7.  Increased cotinine elimination and cotinine-N-oxide formation by phenobarbital induction in rat and mouse.

Authors:  H Foth; J Aubrecht; M Höhne; U I Walther; G F Kahl
Journal:  Clin Investig       Date:  1992 Mar-Apr

8.  Human aggressive responding during acute tobacco abstinence: effects of nicotine and placebo gum.

Authors:  D R Cherek; R H Bennett; J Grabowski
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 9.  Chemical analyses as validators in smoking cessation programs.

Authors:  D D Gilbert
Journal:  J Behav Med       Date:  1993-06

10.  Kinetics of cotinine after oral and intravenous administration to man.

Authors:  P J De Schepper; A Van Hecken; P Daenens; J M Van Rossum
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.